Found 7 articles for: "Ruxolitinib"
Advanced Topical Nonsteroidal Therapies for Atopic Dermatitis: Consensus Statements from an Expert Panel
March 2026 | Volume 25 | Issue 3 | Original Article | 221 | Copyright © March 2026
Background: Advanced topical nonsteroidal therapies are expanding options for atopic dermatitis (AD) by providing targeted anti-inflammatory control without many limitations of l...
Read MoreHalo Seborrheic Keratosis in a Patient of Color With Vitiligo
January 2026 | Volume 25 | Issue 1 | Case Reports | 95 | Copyright © January 2026
A 73-year-old woman with Fitzpatrick skin type V presented with a long-standing brownish-black, three-tone macule on the right anterior thigh that developed a sharply demarcated depigmented halo....
Read MoreManagement of Hailey-Hailey Disease With Ruxolitinib 1.5% Cream
November 2025 | Volume 24 | Issue 11 | Case Reports | 1141 | Copyright © November 2025
Introduction: Benign Familial Pemphigus (Hailey-Hailey Disease [HHD]) is a rare chronic condition, with treatments focusing on managing disease symptoms.Case...
Read MoreRuxolitinib Cream Versus Triamcinolone Cream in Adults With Mild to Moderate Atopic Dermatitis
October 2025 | Volume 24 | Issue 10 | Original Article | 1036 | Copyright © October 2025
Atopic dermatitis (AD), a chronic inflammatory skin disease, is typically treated with topical corticosteroids in patients with mild to moderate disease, creating an ongoing need for nonsteroidal...
Read MoreNovel Clinical Applications of Topical Ruxolitinib: A Case Series
March 2024 | Volume 23 | Issue 3 | Case Reports | 188 | Copyright © March 2024
Topical ruxolitinib, a potent Janus kinase (JAK) inhibitor, has shown significant efficacy in treating inflammatory skin conditions. While its use has already been established in atopic dermatiti...
Read MoreA Review on the Use of Topical Ruxolitinib for the Treatment of Vitiligo
July 2023 | Volume 22 | Issue 7 | Original Article | 664 | Copyright © July 2023
Background: This article describes the clinical trial, safety, and efficacy of ruxolitinib 1.5% cream or repigmentation in patients with vitiligo.Data Sources: A sys...
Read MoreSuccessful Management of Erythema Dyschromicum Perstans Following Topical Ruxolitinib Therapy
March 2023 | Volume 22 | Issue 3 | Case Reports | 297 | Copyright © March 2023
Erythema dyschromicum perstans (EDP) is a rare cutaneous disorder in which patients develop gray or blue-brown macules or patches on their bodies.1 This condition does not appear to have a ...
Read More© 2026 Journal of Drugs in Dermatology. All Rights Reserved. JDD, a peer-reviewed, MEDLINE®/PubMed® indexed journal, offers the dermatology community strong content of utmost quality and relevance on drugs, devices, and methods.
